GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » 3-Year Revenue Growth Rate

VCYT (Veracyte) 3-Year Revenue Growth Rate : 20.80% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte 3-Year Revenue Growth Rate?

Veracyte's Revenue per Share for the three months ended in Dec. 2024 was $1.47.

During the past 12 months, Veracyte's average Revenue per Share Growth Rate was 14.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 20.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 20.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Veracyte was 111.70% per year. The lowest was -24.60% per year. And the median was 9.30% per year.


Competitive Comparison of Veracyte's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Veracyte's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Veracyte's 3-Year Revenue Growth Rate falls into.


;
;

Veracyte 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Veracyte  (NAS:VCYT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Veracyte 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Veracyte's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Executives
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Robert S Epstein director
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John L Bishop director
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080